ERP-Studie zeigt deutlich: Moderne Systeme entlasten den Mittelstand im Alltag

Stuttgart (ots)

Mittelstands-Umfrage: Hoher Modernisierungsdruck trifft auf begrenzte interne Kapazitäten

Über die Hälfte der befragten Unternehmen sieht einen hohen oder sogar sehr hohen Modernisierungsdruck bei dem im eigenen Betrieb eingesetzten ERP-System. Allerdings fehlen vielen Unternehmen die internen Personalressourcen, um genau diese Erneuerung voranzubringen. Dies geht aus dem aktuellen Report "ERP-Herausforderungen 2026/2027" der Stuttgarter Planat GmbH hervor. Für die Studie waren 150 Unternehmen aus dem produzierenden Gewerbe unterschiedlicher Firmengrößen zu ihrer Strategie bezüglich Enterprise Resource Planning (ERP) befragt worden.

Laut Studie bewerten rund 51 Prozent den Modernisierungsdruck als hoch oder sehr hoch. Investitionen in ERP, Digitalisierung oder Prozessautomatisierung sind bei 64 Prozent innerhalb der nächsten zwei Jahre konkret geplant oder zumindest grundsätzlich vorgesehen. Für die Projektplanung bedeutet das: Unternehmen müssen den laufenden Betrieb und die Erneuerung ihrer Abläufe gleichzeitig organisieren. Gerade bei gewachsenen Systemlandschaften ist zu klären, welche bisherigen Anpassungen noch gebraucht werden, welche Abläufe sich vereinfachen lassen und welche Erweiterungen notwendig sind. Dabei ist die Übernahme vorhandener Sonderlösungen keine Selbstverständlichkeit: Was früher eine technische Lücke geschlossen hat, kann heute durch eine Standardfunktion abgedeckt sein. Ein Abgleich zwischen bestehenden Arbeitsweisen und dem künftigen Prozessmodell hilft, unnötige Komplexität im neuen System zu vermeiden.

Ressourcen sind die größte Projekthürde

Fehlende interne Ressourcen sehen 86 Prozent der Befragten als Hürde bei der Modernisierung oder Einführung eines ERP-Systems. Damit ist die Ressourcenknappheit das in der Umfrage am häufigsten genannte Hindernis. Hoher Projektaufwand sowie Datenmigration und Datenqualität folgen mit jeweils rund 83 Prozent Zustimmung (Mehrfachnennungen waren möglich). Kosten oder Budgetrestriktionen sind für rund 77 Prozent ein begrenzender Faktor. Neben dem Finanzierungsplan braucht es deshalb eine realistische Kapazitätsplanung: Das Wissen über Artikel, Fertigungsabläufe und Kundenanforderungen liegt in den Fachabteilungen. Diese müssen auch dann an einem neuen ERP-Projekt mitwirken können, wenn das Tagesgeschäft sie stark beansprucht.

"Ein ERP-Projekt lässt sich nicht allein über das Budget steuern. Die Fachabteilungen brauchen Zeit, um Anforderungen zu klären, Daten zu prüfen und neue Abläufe zu testen", sagt Christian Biebl, Geschäftsführer von Planat. "Eine gute Einführung berücksichtigt diese Aufgaben von Anfang an und verteilt sie so, dass der laufende Betrieb arbeitsfähig bleibt."

Einführungsqualität vor Umsetzungstempo

Bei der Wahl eines Anbieters steht die Qualität von Beratung, Einführung und Projektmanagement an erster Stelle: 73 Prozent nennen sie in der Studie als entscheidenden Faktor. Dahinter folgen ERP-Kompetenz mit 69 Prozent sowie Service und Support nach der Einführung mit 67 Prozent. Die Branchenerfahrung in der fertigenden Industrie ist für 65 Prozent der Befragten entscheidend. Die Geschwindigkeit der Projektumsetzung nennen 45 Prozent. (Mehrfachnennungen waren möglich.)

Das Ergebnis spricht für eine sorgfältige Projektvorbereitung. Ein abgegrenzter erster Einführungsschritt kann helfen, den Aufwand beherrschbar zu halten. Dazu gehören klare Zuständigkeiten, überprüfbare Meilensteine und Unterstützung über den Produktivstart hinaus. Branchenerfahrung erleichtert es, Anforderungen wie Variantenfertigung oder die Planung begrenzter Maschinenkapazitäten früh zu berücksichtigen. Schulungen sollten an den tatsächlichen Aufgaben der Mitarbeiter ansetzen, damit neue Funktionen im Alltag auch genutzt werden. Vor dem Produktivstart sollten die Beteiligten in Form von Integrationstests ihre Geschäftsvorgänge vollständig simulieren, etwa vom Kundenauftrag über die Materialbereitstellung bis zur Auslieferung und Rechnungsstellung. So werden Abhängigkeiten sichtbar, die bei der Prüfung einzelner Funktionen leicht übersehen werden. Für die Umstellung braucht es außerdem einen abgestimmten Ablauf für Datenübernahme, Freigaben und die Betreuung der Anwender in den ersten Betriebstagen.

Entlastung ist das Ziel

Die Befragten erwarten, dass moderne ERP-Systeme helfen, knappe Personalkapazitäten besser zu nutzen. 89 Prozent sehen darin eine Hilfe gegen den Fachkräftemangel, weil sich manuelle Routinetätigkeiten reduzieren lassen. Für die Entlastung der Mitarbeiter im Tagesgeschäft liegt die Zustimmungsquote bei 86 Prozent. Entlastung entsteht beispielsweise dann, wenn Auftragsdaten ohne erneute Eingabe in Einkauf, Lager und Fertigung weiterverwendet werden. Klare Freigaberegeln helfen zusätzlich, Rückfragen und Suchaufwand zu begrenzen. Der Nutzen einer Modernisierung zeigt sich damit auch daran, ob Mitarbeiter weniger Zeit mit dem Abgleich widersprüchlicher Informationen verbringen.

"Die Einführung bindet zunächst Ressourcen. Ihr Ziel muss sein, die Arbeit anschließend spürbar zu vereinfachen", erklärt Biebl. "Deshalb sollten Unternehmen früh festlegen, welche Abläufe sie verbessern wollen und woran sie den Erfolg erkennen. So wird aus einem Softwareprojekt eine nachvollziehbare betriebliche Investition."

Die PLANAT GmbH (www.PLANAT.de) bietet mit ihrer skalierbaren ERP-Standardsoftware einen flexiblen IT-Service "Made in Germany" für den produzierenden Mittelstand. In der Basisversion verantwortet die Software Vertrieb, Beschaffung, Logistik, Produktionsplanung und -steuerung mit Betriebsdatenerfassung und betriebswirtschaftliche Anwendungen. On top können bedarfsgerecht branchenspezifische Softwareinhalte integriert und diverse Add-ons, wie z. B. ein Dokumentenmanagementsystem (DMS) oder Customer-Relationship-Management (CRM), eingesetzt werden. Das innovative, modulare Softwarekonzept ergänzt PLANAT seit 1981 durch branchenspezifische Beratung sowie durch verlässlichen Support.

Pressekontakt:

Kontakt: PLANAT GmbH,

Schönbergstr. 45-47, 73760 Ostfildern (bei Stuttgart), Deutschland,

Tel.: +49 (0)711-16756-0, E-Mail: software@PLANAT.de,

Web: www.PLANAT.de

Ansprechpartner: Cecilia Fischer - E-Mail: cecilia.fischer@planat.de

PR-Agentur: euromarcom public relations GmbH,

E-Mail: team@euromarcom.de, Web: www.euromarcom.de

Original-Content von: PLANAT GmbH, übermittelt durch news aktuell

CC (CLIMATE CHANGE) INVESTMENT FORUM CHAIR AND PRIMA APP FOUNDER SIGN A LETTER OF INTENT AT CC FORUM IN LONDON - PRIMA PLEDGES £10M TO EXPAND CC FORUM

- Max Studennikoff, President of CC Forum "Investment in Sustainable Development" and Alex Zhardanovsky, a serial tech entrepreneur behind PRIMA which aims to monetise the Recommendation Economy has pledged £10M across 2027-2028 to expand CC Forum globally.

- CC Forum has entered into a strategic partnership with AI & Sustainability Alliance endorsed through Magnifica Humanitas initiative announced by Pope Leo earlier this year. The partnership is based on the conviction that AI should be harnessed and directed for a greater good.

- CC Forum Foundation, a UK-based charity was officially launched together with the pledge inviting businesses to commit 1% of their profits to charitable causes.

- The speakers and guests of honour at CC Forum London were inter alia: Professor Jeffrey Sachs, US economist, UN Sustainable Development Solutions Network; Lord Zac Goldsmith, ex- Minister for Environment; Dr. Peter Klasvogt, Rector of Collegio Teutonico of the Vatican; Dr. Stephen Melnik, United World Leaders Chairman; J. Bradley Hilton, Chairman Hilton Family Office; Lord Nat Wei of Shoreditch, Lord Tony Sewell CBE, Runa Alam, Chairwoman of Development Partners International, Per Wimmer, Wimmer Family Office; Simon Littlewoods, Li Family Office Chairman; Alicia Holley-Castillo, Chairwoman of Wealthing Family Office, Phil Lane Jr, Hereditary chief; Chris Smith, Chairman of Smith Family Office and Lyda Tymiak Lindell, partner at Lindell Investments.

- Ludwig Nobel officiated the black-tie Gala Dinner & Awards Ceremony which included soloists from the Royal Opera House and Royal Ballet.

LONDON, Nov. 3, 2026 /PRNewswire/ -- CC Forum's founder Max Studennikoff today announced the signing of a Letter of Intent with PRIMA's founder Alexander Zhardanovsky at last week's CC Forum (27-30 October at the Mayfair Hotel). The LOI includes Alex Zhardanovsky's pledge of ten million pounds to expand CC Forum and its work corralling people of influence to combat climate change and other challenges facing humanity. Max Studennikoff said, "I am very excited about the possibilities that PRIMA's extraordinary pledge brings to the table. It will help us accelerate and amplify our work to address the most pressing issues mankind is confronting today."

The CC (Climate Change) Investment Forum was founded by Max Studennikoff and its first event was held in London in 2018. The forum brings people of influence and affluence together: ultra-high-net-worth individuals, family offices, investors, innovators, scientists and policymakers with the purpose of brainstorming on the biggest challenges facing humanity and fostering investment in sustainable solutions and development for climate change, geopolitical conflicts, poverty, inequality and mental health. Previous CC Forums have been held in Paris, Zurich, Monaco under the patronage of H.S.H. Prince Albert II of Monaco, Bahrain, Dubai and Los Angeles.

For further information or to interview Max Studennikoff or Alexander Zhardanovsky, please contact Alexandra Foley on [email protected].

SOURCE CC Forum

Share this article

- Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of HLA-A*02:01 allele status or line of therapy

- Completed NDA submission in Q3'26 to support the potential U.S. approval of darovasertib plus crizotinib in metastatic uveal melanoma

- Updated data from Hengrui-sponsored Phase 1 trial of IDE849 (DLL3 TOP1 ADC) presented at ESMO 2026 demonstrates robust anti-tumor activity and encouraging survival benefit in relapsed small cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC); initial data from IDEAYA-sponsored global Phase 1/2 trial expected by the end of 2026 / early 2027

- IDEAYA R&D Day scheduled for November 16th to highlight preclinical data supporting rational combinations that exploit MTAP/CDKN2A deficiency in KRAS-mutant cancers

- $1.15 billion in cash, cash equivalents and marketable securities as of September 30, 2026; cash runway guidance into 2030 remains unchanged based on current operating plan

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of targeted therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

"We are encouraged by the continued momentum at IDEAYA during the third quarter, marked by the successful completion of our first NDA filing for darovasertib in metastatic uveal melanoma," said Yujiro S. Hata, Chief Executive Officer of IDEAYA. "We also provided multiple clinical data updates at ESMO on darovasertib to support its potential as a foundational therapy across the entire uveal melanoma treatment journey as well as updated data from IDE849, our DLL3 TOP1 ADC, in relapsed SCLC and NEC. Looking ahead, we are excited to share new preclinical data on our extensive MTAP/CDKN2A franchise in RAS-mutant cancers that provides the scientific rationale in support of the two clinical collaborations we established with Roche and Genentech."

Selected Pipeline Developments and Corporate Updates

Darovasertib for Uveal Melanoma (UM)

- IDEAYA presented clinical data from two ongoing clinical trials in metastatic UM (mUM) at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. The OptimUM-01 update focused on the Phase 2 expansion results in 101 HLA-A*02:01-positive patients, including both treatment naïve and 2L patients who received prior tebentafusp. The OptimUM-02 update builds on positive topline data reported in June showing treatment naïve HLA-A*02:01-negative patients receiving darovasertib plus crizotinib (the darovasertib combination) had a meaningful and statistically significant improvement in median progression free survival (PFS) compared to investigator's choice of therapy as determined by both blinded independent central review (BICR) and investigator assessment. Collectively, the data support the broad potential of the darovasertib combination to drive meaningful clinical benefits for patients with mUM, irrespective of HLA-A*02:01 allele status or line of therapy.

- During the third quarter IDEAYA successfully submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to support a potential U.S. approval of the darovasertib combination in mUM under the Oncology Center of Excellence Real-Time Oncology Review (RTOR) program.

- In primary UM, IDEAYA provided follow-up data at ESMO 2026 from approximately 119 patients enrolled in the Phase 2 OptimUM-09 trial evaluating single-agent darovasertib as a neoadjuvant therapy. Consistent with prior results, >85% of patients treated with darovasertib experienced robust tumor shrinkage, resulting in a 57% eye preservation rate in the enucleation cohort and 74-79% of patients in the plaque brachytherapy cohort achieving a reduced predicted dose of radiation to critical eye structures including the fovea, disc center and lens.

- Due to ongoing site activation and enrollment challenges, IDEAYA has decided to stop enrollment and close the Phase 3 OptimUM-010 trial. This is expected to result in estimated cost savings of $100-125 million that the company will reallocate towards other high-value programs in its pipeline, including potential registrational trials for IDE849 and IDE892.

- IDEAYA is committed to enabling patient access to neoadjuvant darovasertib and plans to submit published data from OptimUM-09 to support potential inclusion in clinical practice guidelines. If successful, guideline inclusion is intended to provide evidence to support the potential clinical benefit of neoadjuvant darovasertib and may allow payor coverage for eligible patients in the United States.

- Following completion of a Type C meeting with the FDA earlier this year, IDEAYA and its partner, Les Laboratoires Servier (Servier), initiated a global Phase 3 registrational trial (OptimUM-011) to evaluate the darovasertib combination in the adjuvant setting of primary uveal melanoma. The trial is expected to enroll approximately 450 patients with increased risk of metastasis, irrespective of HLA status, randomized 1:1 to either 12-months of treatment with the combination or observation. The primary endpoint of the trial is relapse-free survival.

Antibody-drug conjugates (ADCs)

- IDE849 (DLL3 TOP1 ADC): IDEAYA's partner, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), provided a clinical update at ESMO 2026 from its Phase 1 trial in China evaluating IDE849 in patients with relapsed SCLC and NEC.  The data showed substantial anti-tumor activity together with more mature PFS results and encouraging survival outcomes, including median overall survival (OS) of 17.4 months in the 2L SCLC setting. The update also included data from 19 patients with other NECs, showing an ORR and confirmed ORR of 52.6% (10/19; 95% CI: 28.9â75.6) and 36.8% (7/19; 95% CI: 16.3â61.6), respectively, a median PFS of 7.0 months and nine-month OS rate of 82.4%.  IDEAYA plans to provide the first clinical data from its global Phase 1/2 trial of IDE849 monotherapy in extensive-stage SCLC (ES-SCLC) and NEC by the end of 2026 or early in 2027.

- Following successful Type C meetings with the U.S. FDA, IDEAYA plans to initiate two Phase 3 registrational trials with IDE849 in ES-SCLC and NEC by year end.

- The ES-SCLC trial will enroll 400 patients with prior tarlatamab treatment, randomized 1:1 to IDE849 or investigator's choice of therapy. The primary endpoint for accelerated approval will be ORR by BICR, and median OS for full approval. Secondary endpoints will include median DOR by BICR, PFS, and safety. Details of the design of the Phase 3 trial in NEC will be provided at a later date.

- IDE161 (PARG): IDEAYA is also evaluating a Phase 1 combination cohort of IDE849 with IDE161, a potential first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor in patients with ES-SCLC, NEC and other DLL3-overexpressing solid tumors. IDEAYA has previously shared preclinical data demonstrating the mechanism of action of IDE161 in combination with TOP1-payload based ADCs in driving enhanced anti-tumor activity.

- IDE034 (B7H3/PTK7 bispecific TOP1 ADC): IDEAYA plans to provide initial clinical data from its ongoing Phase 1 dose escalation trial in 2027, which is expected to include preliminary safety and efficacy data. IDE034 is a potentially first-in-class B7H3/PTK7 bispecific TOP1 ADC designed to be internalized only when its target antigens are co-expressed on the same tumor cell, which may enhance its selectivity and tolerability profile relative to monovalent antibody formats.

MTAP pathway

- IDE892 (PRMT5): monotherapy expansion has been initiated in the Phase 1 clinical trial evaluating IDE892 in MTAP-deleted solid tumors, with a focus on non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).  The expansion has been initiated at projected efficacious target human exposures where 24-hour target EC90 coverage has been achieved.  The IDE892 maximum tolerated dose has not yet been reached in the ongoing dose escalation.  Pursuant to the clinical collaboration announced with Roche in May, IDEAYA is also targeting initiation of a Phase 1 trial to evaluate IDE892 in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant PDAC by the end of 2026.

- In August, IDEAYA entered into a Clinical Supply Collaboration Agreement with Genentech to evaluate IDE892 in combination with RG6620, a Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant PDAC. Genentech will sponsor and conduct the trial and IDEAYA will provide clinical supply of IDE892.

- IDE397 (MAT2A): a Phase 1/2 combination cohort was initiated to evaluate IDE892 with IDE397, IDEAYA's proprietary MAT2A inhibitor, in MTAP-deleted cancers. Expansion is planned by the first half of 2027 with an initial clinical focus on MTAP-deleted NSCLC. Dual inhibition of MAT2A and PRMT5 has demonstrated durable tumor regressions in several preclinical MTAP-deleted tumor models, including NSCLC.

KAT6/7

- IDE574 (KAT6/7): a Phase 1 dose escalation trial is underway in solid tumors including breast, prostate, colorectal and lung cancer. In October, IDEAYA dosed its first patient in a Phase 1 combination cohort of IDE574 with fulvestrant in estrogen receptor positive (ER+) metastatic breast cancer. IDE574 is a selective, equipotent dual inhibitor of both KAT6 and KAT7 which spares other structurally similar paralogs, including KAT5 and KAT8, which are required for normal cell function. KAT6 and KAT7 are epigenetic modulators of cell identity and lineage commitment programs that are corrupted by oncogenic transformation.

140th Canton Fair: Guochao Style Finds New Expressions in Fashion

GUANGZHOU, China, Nov. 3, 2026 /PRNewswire/ -- What defines "Guochao," or China-chic, today? At a themed release event on "Guochao Fashion" during Phase 3 of the 140th Canton Fair, exhibitors offered diverse answers, illustrating how Chinese cultural heritage can be reinterpreted through materials, craftsmanship and contemporary design.

Heritage Woven into Contemporary Fabrics

One of the highlights was a collection featuring Shu Brocade, the renowned silk jacquard textile from Sichuan and one of China's four great brocades. Products showcasing original patterns inspired by centuries of cultural heritage attracted attention from visitors who photographed the intricate details. By blending traditional weaving techniques with modern aesthetics, the collection revitalizes an intangible cultural heritage craft while connecting it to today's fashion market.

Another approach combined traditional Chinese ramie fabrics with the beauty of Chinese colors. Known for its natural texture and understated elegance, ramie has long been valued for its lightness and breathability. Through innovative dyeing techniques, designers infused these natural fibers with a rich palette inspired by Chinese culture, creating garments that balance simplicity, fluidity and contemporary style. The resulting collection presents a fresh and lightweight interpretation of Eastern aesthetics, bringing traditional cultural elements into today's wardrobes.

Reimagining Tradition Through Design

Beyond fabrics, designers explored how fashion design itself can convey cultural narratives.

One featured collection drew inspiration from traditional Chinese papercutting art and the vitality of nature. Layered fabrics, intricate cutout details and thoughtful tailoring reinterpret the formal language of papercutting, including its symmetry and continuity, through a contemporary lens. The designs celebrate the independence and individuality of modern women while preserving the enduring elegance of Chinese craftsmanship.

A handbag series inspired by the famed painting A Thousand Li of Rivers and Mountains offered yet another expression of Guochao style. The collection draws from the blue-and-green landscape imagery of the Northern Song masterpiece. By transforming classical artistic motifs into everyday fashion accessories, it allows consumers to carry a piece of Chinese cultural heritage wherever they go.

As Phase 3 of the 140th Canton Fair continues under the "Better Life" theme, these creations illustrate how tradition and innovation can coexist. Whether through heritage textiles or artistic reinterpretation, they reflect an evolving lifestyle where cultural confidence, creativity and quality come together to shape a better future.

For more convenient attendance, please click here for pre-registration:

https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

SOURCE Canton Fair

Share this article

Svea Mining appoints DNB Carnegie as liquidity provider.

News provided by

Svea Mining AB

Nov 03, 2026, 05:19 ET

STOCKHOLM, Nov. 3, 2026 /PRNewswire/ --Svea Mining AB (publ) ("Svea Mining" or the "Company") has appointed DNB Carnegie Investment Bank AB (publ) ("DNB Carnegie") as liquidity provider for the Company's shares on Spotlight Stock Market (ticker: SVEA) (ISIN: SE0030252599). DNB Carnegie began the role on October 27, 2026, the Company's first day of trading.

The commitment follows Spotlight Stock Market's rules for liquidity providers. DNB Carnegie will quote bid and ask prices in the share for at least 85 percent of trading hours each day. Each quote will be for at least SEK 5,000 on both the bid and ask side, with a maximum spread of 6 percent. The aim is to improve liquidity in the share and narrow the gap between bid and ask prices.

The agreement has an initial term of six months. After that, it continues until either party ends it with one month's notice. Svea Mining pays DNB Carnegie a fee of SEK 25,000 per month, excluding VAT.

"Having a liquidity provider from day one makes it easier for investors to buy and sell our shares at fair prices. We are pleased to have DNB Carnegie supporting trading in Svea Mining as we build the Company," says Mackenzie Osborne, CEO of Svea Mining.

About Svea Mining AB

Svea Mining AB is a Swedish mineral exploration company exploring for gold, copper and silver across approximately 7,500 hectares in the Skellefteå volcanogenic massive sulphide (VMS) district of northern Sweden, one of Europe's most productive regions for gold, copper and silver for more than a century. The Company holds two exploration permits: the Kalvträsk project (approximately 7,000 hectares) and the Stöverfors project (451.93 hectares), both within or on the margin of a geological system that has produced almost 30 mines and still hosts active mining today. The Company's registered office is in Sweden.

For further information

Mackenzie Osborne, CEO Svea Mining AB Email: [email protected] Website: www.sveamining.com

This information was brought to you by Cision http://news.cision.com

The following files are available for download:

PDVSA Commercial Creditors Committee Launches "National Capital" Initiative to Restructure Commercial Claims and Support Venezuela's Energy Sector

NEW YORK, Nov. 3, 2026 /PRNewswire/ -- The PDVSA Commercial Creditors Committee will announce on November 17, 2026, the launch of National Capital, an initiative designed to address outstanding commercial claims and other trade obligations of Petróleos de Venezuela, S.A. (PDVSA) and its subsidiaries.

At the conference "A voice to move forward: Private Capital in the development of the petroleum industry," National Capital will present a debt sustainability analysis for Venezuelaâprepared by Summa Consulting & Strategyâas well as the results of a national public opinion survey on the debt restructuring process and the private local oil contractors, conducted by Datanalisis.

Addressing Commercial and Trade Claims

Commercial creditorsâincluding oilfield service providers, engineering contractors, suppliers, and construction companiesârepresent a critical pillar of Venezuela's petroleum sector and the country's development.

"Local oil field services, supply and procurement, and construction and engineering companies are essential to supporting Venezuela's energy sector's growth," said Alejandro Dopazo, executive director of oil field services company Grupo Petroamerica C.A. and National Capital's coordinator. "Through the National Capital initiative, we are moving beyond legacy disputes to propose solutions that balance fair recovery for commercial creditors and financing for the operational and capital requirements of national oil contractors."

Key Pillars of the National Capital Initiative:

- Claims Reconciliation & Registry: Establish an independent, reliable procedure for commercial claims and a trade-receivables reconciliation process.

- Value-Recovery & Capital Instruments: Structuring recovery mechanismsâsuch as production-linked instruments or asset-backed structuresâto align creditor recovery with production upside.

- International financing: Propose and structure international financing to expand oilfield services, upgrade technology, and develop the supply chain.

- Governance & Regulatory Alignment: Operating under strict adherence to international legal standards, sanctions frameworks (including U.S. OFAC licensing frameworks), and full transparency.

Strategic Path Forward

The Committee invites eligible commercial creditors, trade suppliers, and claimholders to participate in the National Capital initiative. The Committee is actively engaging financial advisors, legal counsel, and other creditors to ensure the initiative aligns with broader sovereign restructuring efforts.

About the PDVSA Commercial Creditors Committee

The PDVSA Commercial Creditors Committee is an organized forum representing local oil field services, trade suppliers, and engineering and construction contractors with commercial claims against PDVSA and its subsidiaries. The Committee is dedicated to achieving transparent, fair, and sustainable resolutions that support Venezuela's energy sector and the country's development.

For creditor participation inquiries or further details regarding the National Capital initiative, visit www.venpdvcc.org.

Instagram: @capital.nacional

SOURCE Capital Nacional

Share this article

Highlights

- Third quarter U.S. GAAP total diluted loss per share of 36 cents vs. earnings per share of $1.18 in 2025

- Third quarter comparable diluted earnings per share of $1.10 vs. $1.03 in 2025, an increase of 6.8%

- Third quarter comparable operating earnings of $451 million vs. $440 million in 2025, an increase of 2.5%

- Global aluminum packaging shipments increased 4.7% in the third quarter

- Returned $431 million to shareholders via share repurchases and dividends in the first nine months of 2026; on track to return at least $800 million through share buybacks and dividends to shareholders by year-end

- Investing in a new beverage can manufacturing facility in Baruth, Germany, to support long-term customer growth in EMEA and further strengthen Ball's regional manufacturing network

- Announced a new beverage can manufacturing facility in India to support long-term customer growth and further strengthen Ball's manufacturing network in the region

- In 2026, expect comparable diluted earnings per share growth of 10-plus percent and free cash flow in the range of $900 million

- Focused on advancing sustainable aluminum packaging while driving 10-plus percent comparable diluted EPS growth, increasing EVA, generating strong free cash flow, and sustaining long-term value creation in 2026 and beyond

WESTMINSTER, Colo., Nov. 3, 2026 /PRNewswire/ -- Ball Corporation (NYSE: BALL) today reported third quarter 2026 results.

U.S. GAAP Financial Performance

On a U.S. GAAP basis, the company reported third quarter 2026 net loss attributable to the corporation of $94 million or total diluted loss per share of 36 cents, on sales of $4.19 billion, compared to $321 million net earnings attributable to the corporation, or total diluted earnings per share of $1.18, on sales of $3.38 billion in 2025.

Non-GAAP Financial Performance

Ball's third quarter 2026 comparable net earnings were $293 million, or $1.10 per diluted share compared to $280 million, or $1.03 per diluted share in 2025.

"Ball delivered another quarter of strong results, reflecting the power of our customer-focused strategy, disciplined execution and the ownership mindset embedded throughout our organization. In an operating environment that remains dynamic, our teams continued to execute at a high level, driving global volume and operating earnings growth. These results demonstrate the strength of the Ball Business System and our relentless focus on continuous improvement as we work to better serve customers and create long-term value for shareholders," said Ron Lewis, chief executive officer.

Results for the third quarter and first nine months of 2026 and 2025 reflect the segment reporting structure and profitability measure updates adopted in the first quarter of 2026.

Details of reportable segment comparable operating earnings, business consolidation and other activities, business segment descriptions and other non-comparable items can be found in the notes to the unaudited condensed consolidated financial statements that accompany this news release. References to volume data represent units shipped.

Beverage Packaging, North and Central America

Beverage packaging, North and Central America, segment comparable operating earnings for third quarter 2026 were $210 million on sales of $2.06 billion compared to $215 million on sales of $1.64 billion during the same period in 2025. Third quarter sales reflect higher volume and favorable price/mix, primarily attributable to higher aluminum prices.

Third quarter segment comparable operating earnings decreased year-over-year due to higher costs, primarily due to higher operating costs and plant start-up costs, partially offset by favorable price/mix, including the timing of metal pass through to our customers, and higher volume. Year-over-year third quarter segment volume increased low-single digit percent.

Beverage Packaging, EMEA

Beverage packaging, EMEA, segment comparable operating earnings for third quarter 2026 were $170 million on sales of $1.33 billion compared to $164 million on sales of $1.13 billion during the same period in 2025. Third quarter sales reflect higher year-over-year shipments and favorable price/mix.

Third quarter comparable operating earnings reflect higher volume and favorable price/mix, partially offset by higher costs. Year-over-year third quarter segment volume increased mid-single digit percent.

Results for the Beverage Packaging, EMEA segment include the acquired Benepack business and reflect the first quarter 2026 realignment of the company's facilities in India and Myanmar, as well as the former Saudi Arabian business, within the segment.

Beverage Packaging, South America

Beverage packaging, South America, segment comparable operating earnings for third quarter 2026 were $92 million on sales of $653 million compared to $77 million on sales of $508 million during the same period in 2025. Third quarter sales reflect higher volume and favorable price/mix, primarily attributable to higher aluminum prices.

Third quarter segment comparable operating earnings were higher year-over-year driven by higher volumes and favorable price/mix, partially offset by higher costs. Third quarter segment volume increased by a low-double digit percentage year-over-year.

Non-reportable

Non-reportable is comprised of undistributed corporate expenses and the results of the company's global personal & home care business.

On March 21, 2025, Ball closed on a transaction for the aluminum cups business, which resulted in Ball deconsolidating the business. The financial results of the aluminum cups business are presented in other non-reportable through the date of the transaction.

On August 27, 2025, the company sold 41 percent of its 51 percent ownership interest in Ball United Arab Can Manufacturing Company, which resulted in Ball deconsolidating the business and retaining a 10 percent ownership interest. The financial results of the Saudi Arabian business are presented in the beverage packaging, EMEA, segment through the date of the transaction.

Third quarter results reflect higher year-over-year undistributed corporate expenses.

Outlook

"Our third quarter results reflect disciplined execution across the business, supported by global volume growth, operational performance and the stability provided by our contractual passthrough mechanisms. We remain on track to deliver our long-term objective of 4 to 6 percent operating earnings growth while continuing to generate strong cash flow and grow EVA across the business. Our balanced approach to capital allocation enables us to return significant cash to shareholders through share repurchases and dividends while investing in attractive EVA-accretive growth opportunities. Supported by a strong financial position and disciplined financial framework, we remain focused on improving returns, strengthening earnings power and delivering attractive long-term shareholder returns," said Dan Rabbitt, senior vice president and chief financial officer.

"Our strategy remains centered on building long-term value through strong customer partnerships, an engaged and empowered workforce, and disciplined operational and capital deployment decisions. The Ball Business System continues to strengthen our culture of ownership and accountability, while EVA remains the financial framework that guides how we invest, improve and grow the business. We see significant opportunities ahead to deploy capital into EVA-accretive growth projects, including investments that support our customers and strengthen our global manufacturing network. While the external environment remains volatile, we are confident in our ability to build on our momentum, invest behind attractive EVA-accretive opportunities and deliver sustainable growth for years to come," Lewis said.

About Ball Corporation

Ball Corporation (NYSE: BALL) is the global leader in sustainable aluminum packaging solutions, serving a robust portfolio of customers in the beverage, personal care and household products industries. With 16,000 employees in more than 65 manufacturing plants and facilities worldwide, Ball reported 2025 net sales of $13.16 billion. For more information, visit www.ball.com, or connect with us on LinkedIn or Instagram.

Conference Call Details

Ball Corporation (NYSE: BALL) will announce its third quarter 2026 earnings on Tuesday, November 3, 2026 before trading begins on the New York Stock Exchange. At 6:30 a.m. Mountain Time on that day (8:30 a.m. Eastern Time), Ball will hold its regular quarterly conference call on the company's results and performance:

Ball Corporation Third Quarter 2026 Earnings Call

For those unable to listen to the live call, a webcast replay and written transcript of the call will be posted within 48 hours of the call's conclusion to Ball's website at www.ball.com/investors under "news & presentations."

Forward-Looking Statement

This release contains "forward-looking" statements concerning future events and financial performance. Words such as "expects," "anticipates," "estimates," "will," "believe," "continue," "goal" and similar expressions typically identify forward looking statements, which are generally any statements other than statements of historical fact. For example, the forward-looking statements in this news release include statements relating to our plans, strategies, objectives, commitments and guidance. Such statements are based on current expectations or views of the future and are subject to risks and uncertainties, which could cause actual results or events to differ materially from those expressed or implied. You should therefore not place undue reliance upon any forward-looking statements, and they should be read in conjunction with, and qualified in their entirety by, the cautionary statements referenced below. Ball undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Delegation calls for greater recognition of Canadian ownership and control in defence procurement, and clearer pathways from innovation to operational deployment.

OTTAWA, ON, Nov. 3, 2026 /PRNewswire/ -- Today, the Alliance of Canadian Defence Companies (ACDC) leads a national delegation of defence and dual-use companies to Parliament Hill, calling for greater recognition of Canadian ownership and control in defence procurement and a clearer, more agile pathway from testing to procurement.

The delegation is meeting with senior federal officials and parliamentarians to advance recommendations informed by ACDC's ongoing engagement with Canadian defence companies, including individual consultations with close to 90 firms across the country and a member survey. Across these consultations, companies have described difficulties securing contracts following successful military trials, limited visibility into procurement decisions and uncertainty about future defence demand. They have also raised concerns about whether procurement policies adequately recognize Canadian ownership and control, particularly in priority sovereign capability areas.

"Over the past several months, we've spoken with defence and dual-use companies across Canada, from emerging tech developers to established manufacturers. Despite their different capabilities and experiences, we've heard remarkably consistent concerns about procurement, access to opportunities and the certainty needed to invest and grow," said Dasha Cohen, executive director of ACDC. "Our first Hill Day is about bringing those perspectives directly to federal decision-makers, putting forward practical recommendations and building the relationships needed to turn them into meaningful change."

Preliminary findings from ACDC's member survey suggest that greater certainty around future Canadian defence demand could unlock additional hiring, investment and production capacity. Among 49 responding defence and dual-use companies:

- 86% said they would hire additional employees.

- 73% would develop new capabilities.

- 67% would expand production or delivery capacity.

- 67% would increase research and development.

Strengthening Canadian industrial capacity

ACDC is calling for defence procurement policies that distinguish between companies operating in Canada and those that are Canadian-owned and controlled. Beyond ownership, this means considering where intellectual property is held, where key decisions are made and whether critical defence technologies can be produced and maintained in Canada.

As defence spending increases, these distinctions will help determine whether public investment builds lasting Canadian industrial capacity and strengthens Canada's control over capabilities critical to its national security.

Moving Canadian innovation into operational use

ACDC is proposing a graduated procurement approach, with streamlined processes for awarding smaller initial contracts and opportunities for larger orders as technologies meet operational and performance milestones. Earlier engagement with Canadian Armed Forces personnel, clearer procurement timelines and more predictable demand would help companies develop technologies that meet military needs and invest in expanding production. 

"Canada cannot call itself sovereign in space if every satellite it depends on has to launch on another country's rocket. Sovereignty means deploying and operating a capability without asking anyone's permission, and that only holds when the capability is designed, built and controlled in Canada, from the intellectual property down to the software," said Bachar Elzein, founder and CEO of Reaction Dynamics. "Canadian companies are ready to deliver. What they need is procurement that rewards proven milestones and sends a predictable demand signal."

ACDC's delegation includes representatives from North Vector Dynamics, Dominion Dynamics, OVA, PV Labs, Kraken Robotics, Reaction Dynamics, Kepler Communications, JASCO Applied Sciences, Wuxly, Qohash and Canadian Strategic Missions Corporation (CSMC), representing capabilities across autonomous systems, aerospace, marine and space technologies, advanced manufacturing, sensors and cybersecurity.

About the Alliance of Canadian Defence Companies

The Alliance of Canadian Defence Companies (ACDC) is a national trade association representing approximately 200 Canadian-owned and controlled defence and dual-use companies. Founded by co-chairs Eliot Pence of Dominion Dynamics and Paul Ziadé of North Vector Dynamics, ACDC provides a collective voice for domestic industry, advocates for policies that strengthen Canada's sovereign defence-industrial capacity, supports Canadian innovation and improves access to defence procurement opportunities.

SOURCE Alliance of Canadian Defence Companies (ACDC)

Share this article

Federal legislation points to a more connected school safety model in which emergency alerts, 9-1-1, and response ready maps work together

ST. CLOUD, Minn., Nov. 3, 2026 /PRNewswire/ -- As Congress considers bipartisan school safety legislation inspired by Alyssa's Law, GeoComm is highlighting an important operational connection: an emergency alert is most useful when 9-1-1 professionals and first responders can immediately understand where help is needed.

Two federal proposals currently under consideration address different parts of that challenge:

- The ALYSSA Act, H.R. 1524, would require local educational agencies receiving federal elementary and secondary education funding to ensure each school has at least one silent panic alarm for school security emergencies.

- Alyssa's Act of 2025, H.R. 6809, would support the development, testing, and evaluation of panic alarm technology while establishing proposed requirements for emergency response maps purchased with federal funding.

Both bills have been introduced and referred to congressional committees. Neither has been enacted into federal law.

H.R. 6809 provides a particularly important connection between emergency notification and location intelligence. Under the proposal, federally funded emergency response maps would need to be created in a digital geospatial format, accessible on mobile devices, shareable with public safety agencies, interoperable with emergency response systems, capable of displaying individual floors, and verified annually for accuracy, among other requirements.

From an Emergency Alert to an Informed Response

A school's street address may identify the campus, but it may not tell responders which building, floor, room, entrance, or area is involved. That distinction becomes especially important across large or multi-building campuses.

Beyond the proposed federal requirements, location intelligence plays an important operational role in helping schools and public safety agencies prepare for and respond to emergencies. When integrated with emergency communication technology, public safety grade indoor and outdoor maps can help:

- Display an emergency alert or 9-1-1 caller location within the correct campus and building context

- Provide floor-level information in multi-story facilities

- Identify rooms, entrances, access routes, safety equipment, and other relevant features

- Give school personnel, 9-1-1 professionals, and responders access to a shared operating picture

- Keep emergency response information current as facilities change

GeoComm's role complements panic alert and emergency communication technology by providing the mapping and location foundation that can help turn an alert into actionable information.

"Time equals life during a school emergency. Alyssa's Law is about making sure help can be summoned immediately, but effective implementation also requires schools, 9-1-1 centers, and responders to plan together," said Lori Alhadeff, Founder and CEO of Make Our Schools Safe. "Accurate location information can help responders better understand where an emergency is occurring and support a more coordinated response."

Connecting Federal Policy with Practical Implementation

Make Our Schools Safe (MOSS) has been a leading advocate for Alyssa's Law and stronger school emergency preparedness nationwide. MOSS's 2026 Alyssa's Law Solution Guide also recommends geo-location capabilities that can accurately identify the origin of an alert, including mapped devices associated with known rooms or zones.

GeoComm joined MOSS as a 2026 Annual Partner, bringing together MOSS's school safety advocacy and GeoComm's experience delivering public safety grade indoor mapping and location intelligence.

"A panic alert can begin the emergency response, but responders still need to know where to go and what they will encounter," said Jody Sayre, Vice President of Business Development and Partnerships of GeoComm. "Accurate, accessible, and actively maintained indoor maps can help connect that alert to the building, floor, room, and access information needed for a more informed response. That is how location intelligence supports the larger intent behind Alyssa's Law."

Questions Schools and Public Safety Agencies Can Consider Now

Regardless of the outcome of federal legislation, school districts and their public safety partners can evaluate whether their current plans address the full path from emergency notification to response:

- Where does an emergency alert go, and how quickly does it reach 9-1-1 or law enforcement?

- Does the alert provide more information than a campus street address?

- Can telecommunicators and responders identify the correct building, floor, room, or zone?

- Are school maps accessible to the public safety agencies responsible for responding?

- Are maps maintained, securely shared, and tested as part of joint emergency exercises?

- Who is accountable for keeping facility and response information current?

Schools should also review applicable state and local requirements, which may differ from the proposed federal legislation.

To learn more, review the MOSS Alyssa's Law Solution Guide and explore GeoComm School Safety.

About Make Our Schools Safe

Make Our Schools Safe is a national nonprofit organization founded in honor of Alyssa Alhadeff, whose life was tragically taken in the 2018 shooting at Marjory Stoneman Douglas High School. The organization empowers students and staff to help create and maintain a culture of school safety. Its work includes advancing Alyssa's Law, expanding student-led MOSS Clubs, supporting school safety projects, and amplifying the voices of students, educators, and families. Learn more at makeourschoolssafe.org

About GeoComm

GeoComm provides public safety grade location data and maps that technology partners embed to bring operational context and trusted location intelligence into critical workflows. Through indoor and outdoor mapping, flexible integrations, and actively maintained data, GeoComm helps partners strengthen their platforms with better operational context and shared situational awareness. Together, these capabilities help partners deliver the shared operational picture agencies, organizations, and responders need, supporting faster, more informed decisions across critical operations. Learn more at geocomm.com

SOURCE GeoComm, Inc

Share this article

Company to Provide Starting 2027 Growth Framework on Earnings Conference Call

Third Quarter 2026 Highlights

- Total reported revenue of $1.767 billion exceeded guidance midpoint by $14 million, led by organic revenue growth of 9% as reported and 10% in constant currency, with acquired business revenue landing slightly ahead of guidance.

- GAAP EPS of $0.82; Adjusted EPS of $4.10 grew 21% and exceeded guidance.

- Analytical Sciences Division (ASD) grew 8% as reported and 9% in constant currency, led by double-digit instrument and chemistry growth from strong execution, new product innovation, and rising customer testing volume.

- In the Biosciences Division (WBD), reagents grew high single-digits on a prior year comparable basis, reflecting a 400bps acceleration in year-over-year growth, as research and clinical reagents both grew high single-digits; In the Advanced Diagnostics Division (ADx), microbiology grew mid-single-digits on a prior year comparable basis.

- The Company is raising every component of its full-year 2026 guidance, including a $43 million increase to total reported revenue at the midpoint, as new growth vectors layer onto a strong foundation of existing demand.

MILFORD, Mass., Nov. 3, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced its financial results for the third quarter of 2026.

Overall Financial Results

The Company's reported revenue for the third quarter of 2026 was $1.767 billion, reflecting $871 million of organic revenue and $896 million of revenue from the acquired Biosciences and Diagnostic Solutions businesses.

Organic revenue for the third quarter of 2026 was $871 million, compared to $800 million for the third quarter of 2025, representing an increase of 9% as reported and 10% in constant currency.

Revenue from Biosciences and Diagnostic Solutions was $896 million for the third quarter of 2026, compared to $885 million on a prior year comparable basis.

On a GAAP basis, the Company reported a diluted earnings per share of $0.82 for the third quarter of 2026, compared to diluted EPS of $2.50 for the third quarter of 2025, reflecting acquisition-related purchase accounting charges, acquisition-related costs, and restructuring costs.

Adjusted EPS for the third quarter of 2026 grew 21% to $4.10, compared to $3.40 for the third quarter of 2025.

"Our team delivered exceptional results led by best-in-class consumables growth across both our Analytical Sciences and Biosciences divisions, as strong execution, new product innovation, and rising customer testing volume accelerated growth," said Dr. Udit Batra, President & Chief Executive Officer, Waters Corporation. "LC-MS instrument growth also strengthened, growing double-digits in constant currency, driven by robust instrument replacement trends, idiosyncratic growth drivers across GLP-1s, PFAS and India generics, and we continued to outperform the market with our leading solutions for complex biologics."

Dr. Batra continued, "Thanks to the hard work of our teams, we are delivering ahead of schedule on our synergy and integration commitments for our acquired businesses. With improving end market conditions and momentum accelerating across the combined company, we are raising our full year 2026 revenue guidance by $43 million at the midpoint and our fourth quarter guidance calls for double digit growth in both our organic and acquired businesses on a days adjusted basis."

Analytical Sciences Division (ASD)

The Analytical Sciences Division â the former Waters Division, excluding the Clinical Business Unit â delivered reported revenue of $703 million in the quarter, compared to $649 million for the third quarter of 2025.

Biosciences Division (WBD)

The Biosciences Division â formerly known as BD Biosciences â delivered reported revenue of $396 million in the quarter, compared to $387 million for the prior year comparable period.

Advanced Diagnostics Division (ADx)

The Advanced Diagnostics Division comprises the former BD Diagnostic Solutions business and the Clinical Business Unit previously reported within Waters Division.

The Diagnostic Solutions business delivered reported revenue of $500 million in the quarter, compared to $498 million for the prior year comparable period. The Clinical Business Unit delivered reported revenue of $75 million in the quarter, compared to $64 million for the third quarter of 2025.

Materials Sciences Division (MSD)

The Materials Sciences Division â formerly known as TA Division â delivered reported revenue of $93 million in the quarter, compared to $87 million for the third quarter of 2025.

A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website www.waters.com in the Investor Relations section.

Full-Year and Fourth Quarter 2026 Financial Guidance

Full-Year 2026 Financial Guidance

The Company is raising its full-year 2026 organic constant currency revenue growth guidance to the range of 9.1% to 9.7%. Including the effect of currency translation, full-year 2026 organic reported revenue is expected to be in the range of $3.429 billion to $3.447 billion.

The Company is raising its acquired business revenue expectation and now expects full-year 2026 acquired business reported revenue of approximately $3.050 billion on an owned-period basis.

Total Company reported revenue for full-year 2026 is expected to be in the range of $6.479 billion to $6.497 billion.

The Company is updating its full-year 2026 adjusted EPS guidance to the range of $14.60 to $14.70, which represents 11% to 12% year-over-year adjusted EPS growth and is 13% to 14% on a constant currency basis.

Fourth Quarter 2026 Financial Guidance

The Company expects fourth quarter 2026 organic constant currency revenue growth to be in the range of 7.0% to 9.0%. Including the effect of currency translation, fourth quarter 2026 organic reported revenue is expected to be in the range of $984 million to $1.002 billion.

The Company expects acquired business reported revenue for the fourth quarter of 2026 to be approximately $817 million.

Total Company reported revenue for the fourth quarter of 2026 is expected to be in the range of $1.801 billion to $1.819 billion.

The Company expects fourth quarter 2026 adjusted EPS to be in the range of $4.58 to $4.68, which represents 1% to 3% year-over-year adjusted EPS growth.

Starting 2027 Growth Framework

Management will provide the Company's 2027 starting growth framework during its scheduled earnings conference call today at 8:00 a.m. ET, outlining how reshoring, synergies and AI-related demand drivers are expected to shape next year's growth.

Announcing Acquisition of MOBILion Systems, Inc.

The Company also announced today that it has acquired MOBILion Systems, Inc. MOBILion is the pioneer of SLIM high-resolution ion mobility separation technology for complex molecular analysis, which separates molecules by size, shape and charge in milliseconds. The acquisition complements Waters' industry-leading mass spectrometry portfolio and is expected to broaden the Company's entry into the proteomics market. Additional details are available in a separate release issued earlier today.

Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year and fourth quarter. The Company is unable to provide reconciliations of forward-looking presentations of adjusted EPS guidance measures to the most directly comparable GAAP measures. Such reconciliations cannot be prepared without unreasonable efforts due to the inherent difficulty and unpredictability in forecasting and quantifying certain amounts that would be necessary for such reconciliations, including acquisition-related amortization, acquisition and restructuring costs, as well as certain legal, advisory and tax costs, or other costs that may arise, which amounts could be significant and could have a material impact on the Company's future GAAP financial results. All amounts, other than percentages and per share data, are presented in millions of dollars. Certain totals and percentages may not recalculate due to rounding.

Results for the acquired Biosciences and Diagnostic Solutions businesses (the "BDS Businesses") for the prior year comparable period are the quarterly results for the Biosciences and Diagnostic Solutions business units for the three months ended September 30, 2025, as reported in Exhibit 99.1 of the current report on Form 8-K filed by Becton, Dickinson and Company ("BDX") with the Securities and Exchange Commission ("SEC") on November 6, 2025.  This historical financial information reflects the results of operations of these businesses as they were historically managed by BDX in conformity with U.S. GAAP.  Therefore, such historical financial information does not necessarily reflect what these businesses' results of operations would have been had they operated as a part of Waters during the period presented, and does not reflect changes that have occurred since the consummation of the acquisition of these businesses by Waters, including, among other things, changes in the financing, cash management, operations, cost structure and personnel needs or differences in accounting policies.  For example, BDX provided certain services, such as legal, finance, information technology, human resources, and other infrastructure support to the BDS Businesses prior to their acquisition by Waters. Costs of these services were included in the BDS Businesses' results of operations through allocations based upon a proportion of revenue or headcount as determined by BDX in conformity with GAAP. Such allocated costs may not be indicative or necessary if the BDS Businesses operated as a part of Waters during the period presented, nor are they necessarily representative of the costs that may be incurred in the future.